SSR125543A   Click here for help

GtoPdb Ligand ID: 3533

Synonyms: SSR-125543A | SSR125543
Compound class: Synthetic organic
Comment: SSR125543A is a corticotropin releasing factor-1 (CRF-1) receptor antagonist.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 53.6
Molecular weight 482.16
XLogP 7.67
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C#CCN(C(c1ccc(c(c1)F)C)CC1CC1)c1sc(c(n1)c1cc(C)c(cc1Cl)OC)C
Isomeric SMILES C#CCN([C@H](c1ccc(c(c1)F)C)CC1CC1)c1sc(c(n1)c1cc(C)c(cc1Cl)OC)C
InChI InChI=1S/C27H28ClFN2OS/c1-6-11-31(24(13-19-8-9-19)20-10-7-16(2)23(29)14-20)27-30-26(18(4)33-27)21-12-17(3)25(32-5)15-22(21)28/h1,7,10,12,14-15,19,24H,8-9,11,13H2,2-5H3/t24-/m0/s1
InChI Key IEAKXXNRGSLYTQ-DEOSSOPVSA-N
No information available.
Summary of Clinical Use Click here for help
SSR125543 was advanced to Phase 2 clinical evaluation as a therapy for depression and anxiety disorders (see NCT01034995). Development was not progressed further as the preclinical benefits observed in animal stress models did not translate to efficacy in human patients.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01034995 A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder Phase 2 Interventional Sanofi